about
Joint effects between five identified risk variants, allergy, and autoimmune conditions on glioma riskSingle nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancerRationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa RicaMultisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.Determinants of seropositivity among HPV-16/18 DNA positive young women.Common genetic variants and risk for HPV persistence and progression to cervical cancer.Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.Human Leukocyte Antigen Class I and II Alleles and Cervical AdenocarcinomaLack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties.A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia.Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infectionRisk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycleHuman papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinantsEpidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohortHPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.Logistic analysis of epidemiologic studies with augmentation sampling involving re-stratification and population expansionReduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination.Chronic typhoid infection and the risk of biliary tract cancer and stones in Shanghai, China.The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents.A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirusDetection of precancerous cervical lesions is differential by human papillomavirus type.Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda.Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposureAssociation between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialComparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa RicaA comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin LevelsEvaluation of a novel PCR-based assay for detection and identification of Chlamydia trachomatis serovars in cervical specimens.Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.Cervical cancer prevention--cervical screening: science in evolution.
P50
Q23917504-3E9BEACA-0FEF-498A-B4F1-3F73FC3C6A4FQ28730698-76C8C18E-6411-4108-8F1D-C9FA01F7A990Q30300329-C958F87E-F18A-42F6-B504-3D7E690B0B60Q30354637-0DB39B2F-5693-433E-AA63-F7957EBFB4AAQ30970916-E68F26A7-A3F3-4F0E-BDB0-4E3D91666386Q30986936-193656F8-D4BF-47D0-ABA9-AF169EA73F47Q33525051-6EFA4B44-D291-4F85-83BB-B32AC4FB994EQ33723312-B69C959B-58EC-471A-9FB3-C4CAF481D6C3Q33775751-98F55F7E-183A-4D57-A4CE-95BE9B4FC076Q33781541-62133161-A575-481B-85D1-567805481D37Q33793914-D5B58570-CC5F-469A-89EE-374667B9D04CQ33834640-4785B017-0DE1-4C46-9735-FF6116AC71C3Q33953881-2DAFF769-492D-4C1C-9CC5-DC2168289721Q34149348-AD48734F-3885-4E5C-861B-98DC72EC0939Q34154315-42CDCDFA-6C0A-4C13-8EF3-7CD638BDD501Q34187446-188BD19D-9D72-4BCA-B54D-12D1555C33D9Q34267472-9946EEA3-98E7-4D47-9E66-523DDA37280DQ34366883-09AB5C24-DEE0-42E6-9187-E822783AA0DFQ34542304-33902197-496F-470E-9201-17C1AC7BA055Q34612818-3B3B542F-12F1-47CA-A2A5-5781D70B65E8Q34678206-55D3C4D1-0C7E-401F-8FB2-4CAD5C2E86FFQ34736045-B765654A-B8A8-4253-88F1-6C00255FD767Q34974475-20BA42E1-DDDB-4684-ACC5-AEDF711C4E42Q35031294-B6180007-A419-4C61-86E7-1903E86F432FQ35078557-05C79EF7-2241-41CF-A10B-4BBFF10016EFQ35088658-763833B5-7B8D-40E0-B65E-9FE9F1A605B2Q35109451-D0F8C658-691E-4764-8A62-26883929E7E6Q35163630-23E8C9C3-D420-4450-B934-EB2AA4DA4AF7Q35172338-27FE9512-5FC7-40A7-B8BD-D0EDDF743BE0Q35228757-C4FB019D-D048-4DB0-8FDB-E058AC04C65CQ35562771-1AA9ED3B-32C8-4D2B-8044-FBB3FD3C53A7Q35784544-8D702207-1702-4C4C-A5CF-527E3A74AAAEQ35887709-1B4FBC7B-5B9D-488F-8228-D4B47D7A979CQ36054504-8BE98A93-299F-4C9D-B047-9271A4D99403Q36314592-3C85B91B-2A28-4589-BBA4-CB497F227295Q36480943-2C522128-7AA4-4A36-A7F8-1B51EC29ACB4Q36745242-14A230BE-0EC9-468D-864C-74C8555E96C2Q37025594-03411FCD-9E09-4502-96F6-C11B406E134F
P50
description
onderzoeker
@nl
name
Mahboobeh Safaeian
@ast
Mahboobeh Safaeian
@en
Mahboobeh Safaeian
@es
Mahboobeh Safaeian
@nl
Mahboobeh Safaeian
@sl
type
label
Mahboobeh Safaeian
@ast
Mahboobeh Safaeian
@en
Mahboobeh Safaeian
@es
Mahboobeh Safaeian
@nl
Mahboobeh Safaeian
@sl
prefLabel
Mahboobeh Safaeian
@ast
Mahboobeh Safaeian
@en
Mahboobeh Safaeian
@es
Mahboobeh Safaeian
@nl
Mahboobeh Safaeian
@sl